# Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

> **NCT04186845** · PHASE3 · COMPLETED · sponsor: **Blue Earth Diagnostics** · enrollment: 391 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** rhPSMA-7.3 (18F) Injection
- **DIAGNOSTIC_TEST:** Positron emission tomography scan

## Key facts

- **NCT ID:** NCT04186845
- **Lead sponsor:** Blue Earth Diagnostics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-04
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186845, "Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04186845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*